Skip to main content

Advertisement

Table 2 Variations in serum androgen levels and in insulin sensitivity indexes in the general and sub-populations distinguished on the basis of the presence/absence of adverse obstetric outcomes

From: Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes

Group PCOS group Control group
  Total population Adverse outcome No adverse outcome Total population Adverse outcome No adverse outcome
T (ng/mL)       
   Δ(0-12) 0.11 ± 0.02* 0.15 ± 0.01° 0.05 ± 0.02 0.03 ± 0.001 0.04 ± 0.003 0.03 ± 0.002
   Δ(0-20) 0.22 ± 0.01* 0.29 ± 0.02° 0.16 ± 0.01 0.02 ± 0.002 0.03 ± 0.002 0.02 ± 0.004
   Δ(0-32) 0.31 ± 0.02* 0.36 ± 0.01° 0.24 ± 0.01 0.02 ± 0.001 0.03 ± 0.002 0.02 ± 0.004
A (ng/mL)       
   Δ(0-12) 0.16 ± 0.01 0.17 ± 0.01 0.17 ± 0.02 0.13 ± 0.01 0.16 ± 0.01 0.12 ± 0.04
   Δ(0-20) 0.44 ± 0.02 0.43 ± 0.02 0.45 ± 0.02 0.22 ± 0.01 0.20 ± 0.04 0.23 ± 0.03
   Δ(0-32) 0.74 ± 0.01 0.74 ± 0.01 0.74 ± 0.02 0.25 ± 0.01 0.25 ± 0.03 0.24 ± 0.01
DHEAS (ng/mL)       
   Δ(0-12) 32.25 ± 2.51* 35.69 ± 2.1° 28.97 ± 2.8 10.51 ± 2.16 11.01 ± 2.31 9.43 ± 2.77
   Δ(0-20) 175.11 ± 4.92* 184.63 ± 5.2° 166.87 ± 4.5 9.70 ± 1.97 11.26 ± 2.05 9.04 ± 2.52
   Δ(0-32) 185.28 ± 6.42* 193.33 ± 6.13° 172.54 ± 6.98 11.34 ± 2.43 12.12 ± 3.06 9.90 ± 2.28
SHBG (nmol/L)       
   Δ(0-12) 10.71 ± 3.15* 7.48 ± 3.51° 14.13 ± 4.24 26.76 ± 8.34 25.43 ± 8.96 27.61 ± 7.56
   Δ(0-20) 90.36 ± 9.44* 73.55 ± 8.34° 116.45 ± 9.08 141.37 ± 9.21 139.12 ± 12.02 153.11 ± 8.42
   Δ(0-32) 93.69 ± 8.81* 72.79 ± 7.53° 119.81 ± 8.90 275.18 ± 12.88 268.07 ± 11.32 282.16 ± 13.02
FAI (%)       
   Δ(0-12) -1.13 ± 0.73* -0.69 ± 0.34° -1.54 ± 0.77 -2.53 ± 0.47 -2.47 ± 0.29 -2.59 ± 0.42
   Δ(0-20) -0.92 ± 0.51* -0.12 ± 0.09° -1.88 ± 0.54 -3.13 ± 0.62 -2.99 ± 0.89 -3.23 ± 0.55
   Δ(0-32) -1.01 ± 0.90* -0.35 ± 0.06° -1.73 ± 0.49 -3.35 ± 0.51 -3.19 ± 1.01 -3.42 ± 0.47
Fasting insulin (μU/mL)       
   Δ(0-12) 1.93 ± 0.36* 2.10 ± 0.21° 1.24 ± 0.43° 1.02 ± 0.52 1.26 ± 0.73 0.98 ± 0.36
   Δ(0-20) 2.64 ± 1.13* 2.98 ± 1.05° 2.12 ± 1.02° 1.41 ± 0.24 1.58 ± 0.89 1.14 ± 0.41
   Δ(0-32) 2.71 ± 1.55* 3.12 ± 1.23° 2.31 ± 1.51° 1.85 ± 0.73 2.22 ± 0.93 1.44 ± 0.67
GIR (mg/10 -4 U)       
   Δ(0-12) 0.34 ± 0.01* 0.22 ± 0.01° 0.41 ± 0.01 0.12 ± 0.03 0.09 ± 0.01 0.18 ± 0.02
   Δ(0-20) 1.02 ± 0.03* 0.78 ± 0.04° 1.76 ± 0.02 0.13 ± 0.05 0.10 ± 0.01 0.17 ± 0.05
   Δ(0-32) 1.33 ± 0.06* 1.02 ± 0.02° 1.64 ± 0.01 0.25 ± 0.03 0.20 ± 0.04 0.30 ± 0.01
HOMA       
   Δ(0-12) 0.62 ± 0.01* 0.84 ± 0.02° 0.46 ± 0.01 -0.18 ± 0.04 -0.20 ± 0.05 -0.10 ± 0.03
   Δ(0-20) 0.91 ± 0.04* 1.02 ± 0.03° 0.86 ± 0.02 -0.27 ± 0.12 -0.37 ± 0.15 -0.18 ± 0.10
   Δ(0-32) 1.12 ± 0.06* 1.48 ± 0.05° 0.89 ± 0.03 -0.26 ± 0.06 -0.34 ± 0.05 -0.19 ± 0.06
  1. *p < 0.05 vs. control group; °p < 0.05 vs. no adverse outcome.